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Abstract
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known serine 
hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh). Although the 
role of AChE in cholinergic transmission is well known, the role of BChE has not been 
elucidated sufficiently. The hydrolysis of acetylcholine in the synaptic healthy brain cells 
is mainly carried out by AChE; it is accepted that the contribution to the hydrolysis of 
BChE is very low, but both AChE and BChE are known to play an active role in neuronal 
development and cholinergic transmission. Myasthenia gravis (MG) is a muscle disease 
characterized by weakness in skeletal muscles and rapid fatigue. Anticholinesterases, 
which are not only related to the immune origin of the disease but also have only symp-
tomatic benefit, have an indispensable role in the treatment of MG. Pyridostigmine, 
distigmine, neostigmine, and ambenonium are the standard anticholinesterase drugs 
used in the symptomatic treatment of MG. All of these compounds may increase the 
response of the myasthenic muscle to recurrent nerve impulses, primarily by protecting 
the endogenous ACh.
Keywords: acetylcholine, acetylcholinesterase, butyrylcholinesterase, 
anticholinesterases, neostigmine, pyridostigmine, distigmine, ambenonium, 
myasthenia gravis
1. Introduction
The autonomic nervous system (ANS) works out of our request, and it differs 
from the somatic system with this feature. Autonomic afferent and efferent fibers 
enter and exit the central nervous system through the spinal and cranial nerves. 
It connects with the medulla spinalis and intermediate neurons, which mediate 
autonomic reflexes in the brain stem [1, 2]. Changes in the internal and external 
environment and emotional factors affect autonomic activity through fibers, which 
descend from the hypothalamus. ANS shows its effect through neuromediators. 
Acetylcholine (ACh) and noradrenaline (NA) are the main neurotransmitters in 
the autonomic nervous system. ACh is released from all preganglionic endings. 
ACh is secreted from all postganglionic parasympathetic fibers, and it acts through 
muscarinic receptors [3, 4]. Autonomic nervous system disorders may occur with 
an abnormally high parasympathetic activity or abnormally low parasympathetic 
activity and/or abnormally high sympathetic activity or abnormally low sym-
pathetic activity. MG, a neuromuscular junction disease that occurs due to ACh 
receptor deficiency in the postsynaptic membrane at the neuromuscular junction, is 
one of these disorders. The origin of the disease is thymus, because myoid cells form 
the source of receptor antigens. ACh release in the normal muscular junction leads 
to a localized end-plate potential, resulting in muscle contraction [5]. Although MG 
patients have normal nerve anatomy and function, there is a decrease in the number 
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of postsynaptic ACh receptors. During a muscle contraction under normal condi-
tions, the release of ACh, which is caused by impulses along the axon, decreases 
gradually in each impulse. This decrease does not cause problems in the postsyn-
aptic membrane when there is no pathology. However, in addition to the reduced 
number of receptors in MG, the ACh-receptor complex is also decreasing gradually; 
therefore, rapid fatigue is observed [6, 7].
2. Acetylcholine and cholinergic receptors
The neurotransmitter is ACh in all of the preganglionic autonomic fibers 
constituting the peripheral parts of the autonomic nervous system, in all postgan-
glionic parasympathetic fibers and in several postganglionic sympathetic nerve 
fibers, and these ACh release fibers are called cholinergic fibers [8]. ACh is synthe-
sized in the cytosol at the end of the nerve fibers, and then it is transported into 
the vesicles from the membrane of the vesicles (Figure 1). ACh is stored here in a 
very dense manner, with about 10,000 molecules in each vesicle. When an action 
potential reaches the nerve end, a large number of calcium channels are opened 
on the nerve end, since it has a large number of voltage-gated calcium channels. 
Figure 1. 
Biosynthesis, transmission, and inactivation of ACh [3].
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As a result, the calcium concentration in the nerve end increases by 100 times; this 
increases the speed of incorporation of ACh vesicles with the nerve end membrane 
by 10,000 times. This incorporation allows the exocytosis of acetylcholine to the 
synaptic range by causing rupture of many vesicles. About 125 vesicles are usually 
ruptured with each action potential. The ACh is then broken up with AChE in a few 
milliseconds to the acetate ion and choline. Choline is taken back to the nerve end to 
be used in the formation of ACh again [9].
Studies have shown that many tissues respond to stimulation and inhibition are 
generated by compounds, which mimic the action of neuronal release of ACh or the 
neurotransmitter administered externally. Peripheral cholinergic receptors interact-
ing with ACh are found in the parasympathetic postganglionic nerve endings in the 
smooth muscles and neuromuscular junction in the skeletal muscles. Cholinergic 
receptors are divided into two groups, namely nicotinic and muscarinic. The 
distribution of muscarinic receptors in the brain adapts to the distribution of ACh 
[10]. Receptors are mostly found in the striatum, neocortex, hippocampus, superior 
colliculus, locus coeruleus, and pons nuclei; whereas, the quantity of them in the 
hypothalamus, spinal cord, and cortex is low. These receptors in neuromuscular 
motor ends and ganglia are the first neurotransmitter receptors that have been 
isolated and purified in active form. It is contemplated that the receptor is com-
prised of two polypeptide chain monomers, which are connected to each other by 
a disulfide bond and have five subunits. When ACh is bound to these receptors, it 
allows the passage of the small cations such as Ca++, Na+, and K+ by leading to an 
increase in membrane permeability. The physiological effect of this condition is 
the formation of depolarization at the motor ends and consequently the muscular 
contraction or the continuation of nerve stimulation at the neuromuscular junction. 
Muscarinic receptors play an important role in regulating the functions of organs 
stimulated by the autonomic nervous system. The effect of ACh on these receptors 
in parasympathetic synapses may be stimulating or inhibiting. ACh both stimulates 
the secretion by activating the salivary glands and leads to the contraction of the 
respiratory system. The compound also inhibits cardiac contractions and relaxes the 
smooth muscles in the blood vessels. Recent studies have shown that there are five 
subtypes of muscarinic receptors (M1, M2, M3, M4, and M5). M1 is found in neuronal 
structures such as the central nervous system and ganglions, M2 is found in the 
heart, M3 is found in the smooth muscles in the glands, and M4 is also found in the 
striatum and lungs [8–10].
2.1 Cholinesterase enzymes and cholinesterase inhibitors
AChE is a hydrolytic enzyme of the class of the serine hydrolase enzyme, which 
plays a major role in the hydrolysis of ACh in cholinergic synapses of the autonomic 
nervous system and central nervous system [11]. Electron microscopy studies using 
histochemical techniques have shown that this enzyme is located on both the nerve 
endings and the postjunction or postsynaptic membrane at the cholinergic synapses 
or junctions. This enzyme, which is also called main cholinesterase, hydrolyzes 
ACh most rapidly among choline esters. It can also hydrolyze methacholine, but it is 
ineffective against benzoylcholine. A second type of cholinesterase, which is called 
pseudocholinesterase, breaks down acetylcholine more slowly. Because this enzyme 
is the most rapidly broken choline ester butyrylcholine, pseudocholinesterase is 
called butyrylcholinesterase (BChE). Butyrylcholinesterase is not found in synapses 
and does not contribute to the hydrolysis of acetylcholine [12]. Both AChE and 
BChE are polymorphic and exist as homomeric and heteromeric molecular forms 
characterized by subunit relationships and hydrodynamic properties. Heteromeric 
molecular forms contain catalytic subunits linked to the lipid or triple helix collagen 
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tail and are often referred to as asymmetric or A forms of AChE. The G1, G2, and 
G4 forms, which are homomeric hydrophilic globular forms of AChE, contain one, 
two, and four identical subunits, respectively. The G4 form is secreted by neurons 
and secretory cells. An amphiphilic glycophospholipid-bound form is a dimer of G2, 
which has two subunits having a glycophospholipid link to the cell membrane. Less 
polymorphism is observed in BChE, and only hydrophilic and asymmetric forms 
have been defined for this enzyme [11].
The structure of AChE reveals an active site containing a catalytic triad-
glutamate (E327), histidine (H440), and serine (S200) at the base of a narrow 
valley about 20 A depth. This general amino acid arrangement represents the serine 
hydrolase enzyme family. The gorge in AChE is coated with 14 aromatic amino 
acids consisting of phenylalanine, tyrosine or tryptophan, and the base of the gorge 
contains a number of anionic residues, which are collectively responsible for the 
interaction of ACh with the positively charged trimethylammonium group and 
the acceleration of binding of the cationic ligands. BChE contains six less aromatic 
amino acids than AChE in the gorge. These structural studies help to elucidate the 
molecular basis of the specificity between the active center and the ligand. In par-
ticular, the main substrate differences between AChE and BChE can be determined 
by the presence of two phenylalanines (F288 and F290), providing a rigid acyl 
binding pocket in AChE. In addition, replacement of these amino acids with leucine 
and valine to provide a less structurally restricted pocket in BChE can also deter-
mine the main substrate differences between AChE and BChE. In addition, AChE 
contains a peripheral anionic region responsible for allosteric inhibition by cationic 
ligand interactions in the catalytic region. This peripheral anionic region proposed 
by Changeux in 1966 links agents such as propidium to residues around the edge of 
the gorge. This peripheral anionic region may play a role in the catalytic process by 
mediating substrate inhibition [13–17].
The effects of ACh released from autonomic and somatic motor nerves are ter-
minated by enzymatic degradation of the molecule by AChE that is present in high 
concentrations in cholinergic synapses and synthesized in both nerve and muscle 
tissues [18]. The drugs, which inhibit AChE, are called anticholinesterase agents. 
The characteristic pharmacological effects of anticholinesterases occur primarily 
by inhibiting the hydrolysis of AChE by the AChE enzyme in cholinergic pathways. 
Inhibition of cholinesterases induces ACh receptors by leading increased ACh 
in nerve synapses and neuromuscular junction. Continuous stimulation of ACh 
receptors results in cholinergic synaptic paralysis and central and peripheral clinical 
symptoms in the central nervous system, autonomic ganglia, parasympathetic and 
sympathetic nerve endings, and somatic nerves due to the accumulation of ACh 
in the motor end plates. Muscarinic effects due to parasympathetic activity and 
nicotinic effects due to sympathetic activity are seen. The main symptoms and signs 
depend on the balance between muscarinic and nicotinic receptors [8, 18].
Inhibition of the AChE prolongs the life of the neurotransmitter at the junc-
tion, thus resulting in pharmacological effects similar to those observed when 
acetylcholine is administered. AChE is the primary target of these drugs, but 
BChE is also inhibited. Anti-AChEs are used in the treatment of diseases such as 
myasthenia gravis, atony in the gastrointestinal tract, glaucoma, and Alzheimer’s 
disease. These compounds are also used as nerve gases and insecticides. Anti-
AChE agents can be divided into three groups based on their mechanism of 
action: competitive agonists, short-acting inhibitors, and long-acting inhibitors 
[19]. Before World War II, only reversible anti-ChE agents were known and 
their prototype is physostigmine. Organophosphates as highly toxic chemicals, 
which were first developed as agricultural insecticides, were also developed as a 
potential chemical warfare agent shortly before World War II. It is known that 
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the excessive toxicity of these compounds is due to the irreversible inactivation of 
AChE. Thus, organophosphate inhibitors are sometimes referred to as “irrevers-
ible cholinesterase inhibitors.” Strong nucleophiles such as pralidoxime can break 
phosphorus enzyme binding [9, 19].
Anti-AChEs, which are currently used for treatment in the postopera-
tive period of intestinal system and atony of the smooth muscles of bladder, 
glaucoma, myasthenia gravis, and termination of the effects of competitive 
neuromuscular muscle relaxants produce nonselectively both muscarinic and 
nicotinic effects as indirect effects by increasing the ACh concentration. Long-
acting and hydrophobic ChE inhibitors are also the only inhibitors with limited, 
well-documented efficacy in the treatment of dementia symptoms of Alzheimer’s 
disease [8, 20].
MG is a muscle disease characterized by weakness in skeletal muscles and rapid 
fatigue. Anti-AChEs, which are not only related to the immune origin of the disease 
but have only symptomatic benefit, have an indispensable role in the treatment of 
MG. Pyridostigmine, distigmin, neostigmine, and ambenonium are the standard 
anticholinesterase drugs used in the symptomatic treatment of MG. All of these 
compounds may increase the response of the myasthenic muscle to recurrent nerve 
impulses, primarily by protecting the endogenous ACh [8, 21, 22].
2.1.1 Pyridostigmine
The most commonly used anti-ChE in daily treatment is pyridostigmine bro-
mide (Figure 2). The effect of the drug starts in 15–30 min, reaches maximum 
in 1–2 hours, and lasts 3–4 hours or longer. Pyridostigmine bromide, used for 
the treatment of MG and for protection against exposure to nerve agents, is a 
carbamate-derived reversible AChE inhibitor [23–25]. Due to the quaternary amine 
structure, it is relatively weakly absorbed from the gastrointestinal system. The 
elimination of half-life of pyridostigmine bromide after a single dose of 60 mg in 
healthy volunteers was found to be 200 min. This requires frequent usage. Ninety-
nine percent of AChE inhibitors, including pyridostigmine bromide, are adminis-
tered orally [26–28].
2.1.2 Distigmine
Distigmine is a carbamate-derived reversible ChE inhibitor. The compound 
synthesized chemically by Schmid has a chemical structure consisting of two 
molecules of pyridostigmine bonded together by hexamethylene bonds (Figure 3). 
Distigmine is clinically used in some Asian and European countries, including Japan 
and Germany, and the main clinical indication for distigmine is myasthenia gravis. 
Figure 2. 
Structure of pyridostigmine bromide.
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However, in Japan, distigmin was also used for glaucoma and underactive bladder 
[29, 30].
2.1.3 Neostigmine
Neostigmine (Figure 4) is commonly used to reverse nondepolarizing neuro-
muscular blocking agents. The drug increases the rate of recovery from moderate 
nondepolarizing neuromuscular blockade and reduces the incidence of residual 
blockade. However, doses of neostigmine used in clinical practice may cause muscle 
weakness when administered after complete recovery from neuromuscular block-
ade. Since the first studies investigating the effects of neostigmine were performed 
in anesthetized patients, the results may be mixed with the presence of anesthetic 
agents, which are known to be in the neuromuscular blockade. Later, the effect of 
neostigmine was supported by the studies that the volunteers did not receive anes-
thetic agents. However, the effects of neostigmine on maximum voluntary muscle 
strength have not been previously investigated [31, 32].
2.1.4 Ambenonium
In addition, compounds, which are structurally different from the above-men-
tioned carbamates for the treatment of MG, are also used. One of them, bisqua-
ternary inhibitor ambenonium dichloride (Figure 5), is known to be one of the 
compounds with the highest inhibition ability against AChE in sub-nM range [33].
The superior effect potential is unique for the compound, which does not form 
any covalent bonds with the active site of the enzyme. Binding studies on the AChE-







convenient contacts with the amino acids of the catalytic and peripheral AChE sites. 
Ambenonium produces less muscarinic side effects than carbamates. Unlike short-
acting anti-AChE compounds, it is advantageous because it produces a larger and 
longer-lasting therapeutic effect during the night and waking period. In addition, 
the bisquaternary structure inhibits the passage from blood-brain barrier (BBB) 
after a conventional oral or intravenous route of administration. Another anti-
AChE compound, edrophonium chloride (Figure 6), is used as a diagnostic tool for 
MG. It has a rapid onset and short pharmacological effect, so it cannot be used for 
therapeutic purposes [33, 34].
The optimal single oral dose of the anti-ChE agents can be determined empiri-
cally, when the MG is diagnosed. Basic records are made for a range of signs and 
symptoms, which reflect comprehension strength, vital capacity, and the strength 
of various muscle groups. The patient is given an oral dose of pyridostigmine at 
30–60 mg, neostigmine at 7.5–15 mg, or ambenonium at 2.5–5 mg. Improvement in 
muscle strength and changes in other symptoms are recorded at frequent intervals 
until they return to the baseline state. After a baseline hour or longer, the drug is 
reintroduced, the dose is increased to one and a half times the initial amount,  
and the same observations are repeated. These repeats continue with increments 
of half the initial dose until the optimal dose is achieved. The duration of action 
between the oral doses is required to maintain the muscle strength of these drugs, 
which is usually 2–4 h for neostigmine, 3–6 h for pyridostigmine, or 3–8 h for ambe-
nonium. However, the required dose may vary from day to day. Physical or emo-
tional stress, intercurrent infections, and menstruation usually require an increase 
in the frequency or size of the dose. Unpredictable exacerbations and remissions of 
the myasthenic condition may require adjustment of the dosage. Pyridostigmine 
has sustained release tablets containing a total of 180 mg, 60 mg of this is released 
immediately and the drug concentration is 120 mg for several hours. This prepara-
tion is valuable in maintaining patients in periods of 6–8 h, but it should be limited 
to use before bedtime [5, 8, 35].
There is always a risk of cholinergic crisis, if the effects of anti-ChE drugs are 
weak and there is no any improvement in the symptoms of the disease even with 
high doses of AChE. In cholinergic crisis, nausea, vomiting, sweating, saliva-
tion, colic, diarrhea, miosis, bradycardia, etc., are observed and myasthenic 
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certain antibiotics, and general anesthetics prevent neuromuscular transmission. 
Therefore, the application of these drugs to patients with MG requires an appropri-
ate adjustment of the anti-ChE dose and other measures [8].
2.2 Newly developed cholinesterase inhibitors for MG
Muscarinic cardiovascular and gastrointestinal side effects of anti-ChE agents 
can usually be controlled by atropine or other anticholinergic drugs. However, these 
anticholinergic drugs mask many side effects of an excessive amount of anti-ChE 
agents. Tolerance in most patients may eventually lead to muscarinic effects [5, 7, 
35, 36]. For these reasons, it is aimed to investigate more effective drugs for the 
treatment of MG and to prevent the hepatotoxicity and known gastrointestinal 
side effects, while creating the targeted pharmacological effect with the synthetic 
analogues at the development stage.
Musilek et al. performed the synthesis of 20 new bis-isoquinolinium inhibitors 
(Figure 7) in a study and determined whether the compounds would be effective 
in the treatment of MG. They evaluated the newly prepared compounds in vitro on 
human recombinant AChE and human plasmatic BChE and compared the inhibi-
tory capabilities of the compounds expressed as IC50 with ambenonium dichloride, 
edrophonium chloride, BW284c51, and ethopropazine hydrochloride, which have 
been selected as standard. In three of the compounds they have obtained, they had 
promising results in which their compounds inhibited both enzymes better than or 
similar to edrophonium and BW284c51, however, worse than ambenonium in vitro. 
The kinetic assays are confirmed noncompetitive inhibition of human-recombinant 
AChE (hAChE) with two promising new compounds selected [37].
In a study in which neostigmine, pyridostigmine, and physostigmine 
quaternary phenylcarbamates were synthesized and evaluated their activity, 
N-monophenylcarbamate analogues together with their precursors of neostigmine 
methyl sulfate and pyridostigmine bromide and the N-methylammonium analogues 
of phenserine, tolserine, cymserine, and phenylethylcymserine were synthesized 
as long-acting peripheral inhibitors of AChE or BChE (Figure 8). According to 
the results of the study, only N-phenylcarbamate of 3-dimethylamiophenol to 
N-phenylcarbamate of 3-hydroxy-1-methylpyridinium bromide compounds had 
marginal ChE inhibitor of activity and compound N(1)-methylammonium bromide 
of (−)-phenserine, (−)-tolserine, (−)-cymserine, and (−)-phenylethylcymserine 
were strong anti-ChEs [38].
Monarsen (EN101) is an antisense oligodeoxynucleotide, which acts at the level 
of mRNA and selectively reduces the production of The enzymatic isoform of read-
through AChE (AChE-R) by the destruction of the AChE-R mRNA. This compound 
selectively lowers the AChE-R levels in both blood and muscle, but, does not affect 
the synaptic variant of synaptic AChE (AChE-S). It was tested in experimental 
Figure 7. 
Structure of bis-isoquinolinium derivatives.
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autoimmune MG rats that oral or intravenous administration of EN101 reduced 
AChE in blood and muscle and increased survival, muscle strength, and disease 
severity. The stabilization of the reduction of the compound motor action potential 
(CMAP) on the responsive neurostimulation system and muscles was also observed 
during the entire treatment. This effect has been found to be comparable to that of 
pyridostigmine, which is worn out for hours and causes significant fluctuations in 
muscle strength. It was also found that clinical and electrophysiological improve-
ment was associated with a decrease in autoimmune responses [39–41].
3. Conclusions
Anti-ChEs have an indispensable role in the symptomatic treatment of the 
MG, which is not directed against the immune origin. AChE inhibitors improve 
neuromuscular conduction by preventing disruption of circulating ACh in the 
neuromuscular junction. The compounds used in the treatment of MG have a 
positive charge in the molecule to provide the peripheral effect of the action and 
minimal blood-brain barrier penetration. However, the most prescribed carbamate 
inhibitors may cause many serious side effects, such as carbamylation of AChE. As 
a result, it is important to individually arrange treatment for each MG patient. The 
effect of treatment should be optimized for vital muscles such as respiratory and 
swallowing; because, different muscles are affected by varying levels. Since the 
nonselective AChE inhibitors are the most effective compounds at the beginning 
of MG, the dosage of AChE inhibitors is ideally reduced as they develop strength 
by immunosuppressive therapy. Decrease in activity over time may be related to 
increased levels of the AChE-R isoform, which may cause morphological and physi-
ological abnormalities in the neuromuscular junction. Myasthenia gravis (MG) is 
usually caused by antibodies either to the acetylcholine receptor (AChR) or to the 
muscle-specific tyrosine kinase (MuSK) or at the neuromuscular junction. Patients 
with MuSK antibodies generally do not respond to the treatment; whereas, patients 
with AChR antibodies respond specifically to the treatment. For these reasons, 
EN101, a selective AChE inhibitor that specifically targets the isoform of AChE 
(AChE-R), has been developed recently and the AChR-antibody may be important 




Structure of neostigmine N-phenylcarbamate of 3-dimethylamiophenol and 3-hydroxy-1-methylpyridinium 
and N(1)-methylammonium bromide of (-)-phenserine, (-)-tolserine, (-)-cymserine, and 
(-)-phenylethylcymserine.
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